RxDoctor Payments Data

Megan Boytek

Family · Charleston, WVNPI 1225624034

Payments from drug & device makers

$4,078in general payments, 2019–2025

Across 196 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Mallinckrodt Hospital Products Inc.$609
  • Otsuka America Pharmaceutical, Inc.$407
  • Travere Therapeutics, Inc.$342
  • Novartis$310
  • Calliditas Therapeutics US Inc.$285
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,03199%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,078 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$24,930
Medicare patients
262
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol13$19,724
LokelmaSodium Zirconium Cyclosilicate13$8,166
Hydralazine Hcl92$1,482
Losartan Potassium81$773
Doxazosin Mesylate24$676
Potassium Chloride27$452
Tamsulosin Hcl23$329
Calcitriol31$316
Amlodipine Besylate83$313
Furosemide56$290
Clonidine Hcl41$287
Metoprolol Succinate13$272
Carvedilol31$235
Lisinopril25$187
Allopurinol16$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,037$27,89026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →